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1. Introduction 
Apoptosis is an essential part of the normal development. The homeostatic balance between 
cell proliferation and cell death rate is critical for maintaining normal physiological 
processes. Aberrant regulation of apoptotic cell death mechanisms is one of the hallmarks of 
cancer development and progression, and many cancer cells exhibit significant resistance to 
apoptosis signalling [1]. Triggering of apoptosis can be achieved via the activation of two 
distinct molecular pathways, the extrinsic or death receptor pathway or via the intrinsic or 
mitochondrial apoptotic cascades. Both pathways lead to the hierarchical activation of a 
family of cysteine proteases called caspases [2], that cleave a series of cellular substrates 
which induce changes including chromatin condensation, internucleosomal DNA 
fragmentation, membrane blebbing and cell shrinkage [3]. Extrinsic pathway is activated 
from outside the cell by proapoptotic ligands that interact with specialized cell surface death 
receptors, including CD95 and TNF-related apoptosis-inducing ligand (TRAIL) receptors 
[4]. After binding to receptors apoptosis is triggered by the intracellular formation of a 
death-inducing signalling complex (DISC) that consists of FAS-associated death domain 
(FADD) and procaspase-8 and 10 [5,6]. As a result, this protein complex activates 
procaspase-8 and 10 inside itself, hence triggering procaspase-3 to execute the apoptosis 
process [7]. The mitochondria (intrinsic) pathway is activated from inside the cell by severe 
cell stress, such as DNA or cytoskeletal damage, inducing mitochondrial outer membrane 
permeabilization and transcription or post-translational activation of BH3-only proapoptotic 
B-cell leukemia/lymphoma 2 (Bcl-2) family proteins [4]. This permeabilization allows the 
release of apoptogenic proteins, including cytochrome c and second mitochondria-derived 
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activator of caspase (Smac; also known as DIABLO), from the mitochondrial intermembrane 
space into the cytosol [8]. Cytochrome c assembles with apoptotic protease-activating factor-
1 (Apaf-1) to activate caspase 9. This caspase, in turn, activates the effector caspases 3, 6, and 
7, which carry out apoptosis [4]. Smac promotes caspase activation and apoptosis by 
neutralization of several IAP proteins, including XIAP, c-IAP1 and c-IAP2 [9,10] 
Chemotherapeutic agents act by inhibiting tumour cell proliferation and survival and most 
of them can kill tumour cells by activating common apoptotic pathways [11]. Therefore, 
apoptosis plays an important role in the treatment of cancer as it is a popular target of many 
treatment strategies. 5-fluorouracil (5-FU), an antimetabolite analogue of uracil employed 
primarily in the treatment of a variety of solid malignant tumours, leads to a wide range of 
biological effects which can act as triggers for apoptotic cell death [12,13]. However, 
resistance to the drug remains a major clinical problem. Given that many of the apoptotic 
regulators altered in multidrug resistant tumours have been identified, one new approach to 
therapy is to restore apoptotic potential through genetic or pharmacological methods [14]. 
Moreover, since defects in the mediators of apoptosis may account for chemo-resistance, the 
identification of new targets involved in drug-induced apoptosis is of main clinical interest. 
Recently, we have identified the ds-RNA-dependent protein kinase (PKR) as a key 
molecular target of 5-FU involved in apoptosis induction, in a p53 -independent manner. 
These results suggest the clinical importance that the PKR status could play in response to 
chemotherapy based on 5-FU. Moreover, the effectiveness of 5-FU cytotoxic activity induced 
by IFNα, especially in cancer cells expressing a mutated form or lacking p53, but with a 
functional PKR, might have relevant clinical application in patients [15] . 
The increased knowledge of some of the molecular components of the apoptosis signalling 
pathways has paved the way for the generation of more specific agents that target one 
crucial signalling component. This has allowed a change in anticancer therapy trends, from 
classic cytotoxic strategies to the development of new non-harmful therapies which target 
the apoptosis response selectively only in tumour cells. Moreover, these strategies overcome 
the adverse effects associated with cytotoxic drugs and increase their anti-cancer activity. 
Novel antitumour drugs have been synthesised such as 5-FU O,N-acetals and benzo-fused 
seven-membered O,N-acetal in which the 5-FU moiety was changed for the naturally-
occurring pyrimidine base uracil, which induced cell cycle-mediated apoptosis in breast and 
colon cancer cells [16,17,18,19]. The mechanism of action of these drugs was mainly centred 
on positive apoptosis regulatory pathway genes, and the repression of genes involved in 
carcinogenesis, proliferation and tumour invasion. In addition, these drugs were more 
selective against tumour cells with lower toxic effects in non-tumour cells [20,21].  
As over-expression of IAP proteins frequently occurs in various human cancers and has 
been linked to tumour progression, chemo-resistance and poor prognosis, it is not 
surprising that IAP proteins are considered to be attractive targets for improve outcomes for 
patients with solid tumours and hematologic malignancies [22,23]. IAPs are also attractive 
as therapeutic targets because their inhibition does not appear to be toxic to normal adult 
cells [24]. Several therapeutic strategies have been designed to target IAP, including a small-
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molecule approach that is based on mimicking the IAP-binding motif of the endogenous 
IAP antagonist Smac [25]. Other therapies involve antisense strategies and short-interfering 
RNA (siRNA) molecules [26,27]. There is increasing interest in therapeutic drug 
development targeting the IAP family.  
MicroRNAs (miRNAs) are small RNA gene products that regulate the activity of messenger 
RNAs by antisense base pairing. They are involved in stem-cell self-renewal, cellular 
development, differentiation, proliferation, and apoptosis [28]. In cancer, miRNAs function 
as regulatory molecules, acting as oncogenes or tumour suppressors [29] and they are 
strongly related to the apoptosis. New insights indicate that many miRNAs are anti-
apoptotic and mediate this effect by targeting pro-apoptotic mRNAs or positive regulators 
of pro-apoptotic mRNAs [30]. Conversely, many pro-apoptotic miRNAs target anti-
apoptotic mRNAs or their positive regulators [31]. Therefore, their inhibition leads to the 
induction of programmed cell death, suggesting a promising miRNA treatment for cancer. 
Several drugs may have the ability to modulate the expression of miRNAs by targeting 
signalling pathways that ultimately converge on the activation of transcription factors that 
regulate miRNA encoding genes.  
Evasion of apoptosis is one of the main mechanisms involved in tumourigenesis and drug 
resistance. Most cancers have a small population of tumour cells, as few as 1%, with stem 
cell characteristics and the capacity for self-renewal, termed cancer stem cells (CSCs). A 
malignant tumour can be viewed as an abnormal organ in which small populations of 
tumourigenic CSCs have escaped the normal limits of self-renewal, giving rise to 
abnormally differentiated cancer cells that contribute to tumour progression and growth 
[32]. These CSC express high levels of ATP-binding cassette (ABC) drug transporters, 
providing for a level of resistance [33]; are relatively quiescent; have higher levels of DNA 
repair and a lowered ability to enter apoptosis . Several cancer therapy approaches targeting 
ABC transporters and increasing apoptosis could be employed to selectively and more 
efficiently kill CSC. 
The current review will focus on recent development of several therapeutic strategies, which 
interfere with apoptosis and are currently used or tested for treatment of cancer. They 
induce cancer cell death or enhance the responsiveness of cancer cells and CSCs to certain 
cytotoxic drugs. Some of them such as caspases activators, indirectly modulators of 
apoptosis or agents targeting apoptosis-related proteins are still in their preclinical or 
clinical trials. We also include future approaches directed to target apoptotic pathways with 
promising application in patients with cancer. 
2. Novel apoptotic markers/targets in cancer  
The main goal in cancer therapy is the abrogation of tumour cell growth and proliferation, 
and ultimately the complete elimination of tumour cells. It is commonly accepted that 
tumour cells treated with anticancer agents undergo apoptosis, and that cells resistant to 
apoptosis often do not respond to anticancer therapy [34]. Moreover, it is widely 
demonstrated that some oncogenic mutations suppressing apoptosis may lead to tumour 
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initiation, progression or metastasis [11]. Apoptosis plays a major control role in cell death 
when DNA damage is irreparable and multiple stress-inducible molecules have been 
implied in transmitting the apoptotic signal [35]. Because of the potential detrimental effects 
on cell survival in case of inappropriate activation of apoptosis programs, apoptosis 
pathways have to be tightly controlled. However, the concept that apoptosis represents the 
major mechanism by which cancer cells are eliminated may not universally apply and 
caspase-independent apoptosis or other modes of cell death have also to be considered as 
cellular response to anticancer therapy [36]. 
Different determinants of drug resistance exist, including loss of cell surface receptors or 
transporters, altered metabolism, or mutation of specific apoptotic target [37]. The apoptotic 
signalling pathways are regulated by numerous hub proteins such as p53, Bcl-2, NFkB and 
MAPKs which function in common. In the following sections, we will summarize some of 
the cellular proteins considered as potential apoptotic biomarkers in cancer. 
1- The tumour suppressor p53 is an important pro-apoptotic factor and tumour inhibitor, 
and numerous anti-tumour drugs would exert their functions through targeting p53-related 
signalling pathways. Some clinical investigations indicated that under abnormal situations 
such as chemotherapy and UV or DNA damage may occur and activate the expression of 
p53. Activated p53 protein binds to the regulatory sequences of a number of target genes to 
initiate a program of cell cycle arrest, DNA repair, apoptosis, and angiogenesis [38]. If the 
damage cannot be repaired completely, over-activation of p53 leads to the tumour growth 
stagnation or even apoptosis [39,40]. Loss of p53 function is critical in tumourigenesis, and 
alterations to the p53 gene (mutations, often resulting in protein over-expression) are 
frequent events in cancer. Associations of p53 tumour alterations with patient prognosis and 
response to adjuvant chemotherapy have been widely studied, and findings are 
contradictory. The fluoropyrimidine 5-FU is widely used in the treatment of a range of 
cancers including colorectal cancer and breast cancer [41,42,43], but resistance to the drug 
remains a major clinical problem. P53 was the first target described for 5-FU- induced 
apoptosis, however, although several reports have demonstrated that 5-FU-induced 
apoptosis is dependent on the tumour suppressor p53 protein, apoptosis can also occur in 
mutant p53 cell lines [44,45,46,47]. Moreover, the relationship between p53 status and 
sensitivity to chemotherapeutic drugs, including 5- FU, is still controversial. In clinical 
studies in which adjuvant chemotherapy– treated and non-treated groups could be 
analyzed, stage III colorectal patients whose tumours demonstrated no p53 alterations 
experienced significantly longer survival following 5-FU–based chemotherapy than patients 
whose tumours over-expressed p53 [48,49]. However, other studies in colon cancer patients 
failed to demonstrate correlations between p53 alterations and benefit from adjuvant 
therapy [50,51]. The identification of new targets involved in 5-FU-induced apoptosis could 
contribute to clarify the controversy results obtaining in clinic.  
2- Recently, we have identified the interferon-induced protein kinase PKR, as a molecular 
target of 5-FU with an interesting role in the apoptosis induced by this chemotherapeutic 
drug [15]. The double-stranded RNA (dsRNA)-dependent kinase PKR was initially 
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identified as an innate immune anti-viral protein approximately 35 years ago [52,53]. Since 
then, PKR has been linked to normal cell growth and differentiation, inflammation, cytokine 
signalling, and apoptosis [54]. PKR is a serine/threonine kinase, characterized by two 
distinct kinase activities: autophosphorylation, which represents the activation reaction, and 
phosphorylation of eIF-2α [55,56], which impairs eIF-2 activity, resulting in inhibition of 
protein synthesis [57]. In addition to its translational regulatory function, PKR has a role in 
signal transduction and transcriptional control through the IkB/NF-kB pathway [58,59]. PKR 
is activated in response to dsRNA of cellular, viral, or synthetic origin. PKR can also be 
activated by polyanions such as heparin, dextran sulfate, chondroitin sulfate, and poly-L-
glutamine [60]. A range of cellular stresses can also activate PKR, such as arsenite, 
thapsigargin, H2O2, ethanol and ceramide [61,62,63] presumably through the PKR-
associated activator (PACT)/RAX protein [64]. Moreover, it is induced by interferon type I 
and mediates in part, several functions of these cytokines. Altered PKR activity has been 
shown to play a role in neurodegenerative diseases (Alzheimer’s, Creutzfeldt–Jakob, 
Huntington’s, and Parkinson’s) and cancer [65,66,67,68,69,70,71,72,73,74]. 
Over-expression or continued activation of PKR leads to apoptosis [75,76,77]. PKR mediates 
the apoptosis induced by several viruses and cellular stresses [78] by activation of intrinsic 
and extrinsic apoptosis pathways through the FADD/caspase 8 and mitochondrial 
APAF/caspase 9 activation pathways [79,80]. Recently, PKR has been shown to play an 
important role in apoptotic cancer cell death induced by 5-FU, doxorubicin and etoposide 
[15,81,82] and the antitumour activity of tumour suppressors like p53 and PTEN [81,83]. 
Preclinical studies in mice have shown than in tumours which do not express sufficient 
levels of PKR are more resistant to doxorubicin and etoposide that tumour expressing 
higher PKR levels. We have demonstrated that PKR is up-regulated and activated in colon 
and breast cancer cell lines by inducing apoptotic cell death in response to 5-FU treatment. 
In addition, cancer cell lines deficient in PKR expression were more resistant to the cytotoxic 
effect of 5-FU with an IC50 being 2-3 fold higher than cells expressing an active PKR protein. 
Moreover, apoptosis mediated by PKR in response to 5-FU occurred independently on p53 
status highlighted the importance that both p53 and PKR play in the 5-FU-induced cancer 
cell death, and the relevance acquired by PKR in tumour cells where p53 is mutated. Such 
results raise the importance of determining PKR status in tumours from patients treated 
with 5-FU-based chemotherapy [15]. 
3- One pathway being targeted for antineoplastic therapy is the Bcl-2 family of proteins (Bcl-
2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that bind to and inactivate BH3-domain pro-
apoptotic proteins. It is controversial whether some BH3-domain proteins (Bim or tBid) 
directly activate multidomain pro-apoptotic proteins (e.g., Bax and Bak) or act via inhibition 
of those anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that 
stabilize pro-apoptotic proteins [84]. Since the anti-apoptotic properties of Bcl-2 were 
discovered, the over-expression of Bcl-2 conferring chemoresistance was reported, and the 
3-D protein structure of Bcl-XL was determined. These properties have contributed to the 
development of protein inhibitors. The first agent targeting Bcl-2 that entered clinical trials 
was a Bcl-2 antisense (oblimersen sodium), which showed chemosensitizing effects when 
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combined with conventional chemotherapy drugs in chronic lymphocytic leukemia (CLL) 
patients, leading to improved survival [85,86]. More recent advances include the discovery 
of small molecule inhibitors of the Bcl-2 family proteins. They are designed to bind the 
hydrophobic groove of anti-apoptotic Bcl-2 proteins in place of BH3-only proteins (i.e., BH3-
mimetics). They can oligomerize Bax or Bak, which can subsequently depolarize 
mitochondrial membrane potential to release cytochrome c. To date, one Bcl-2 antisense and 
three small molecule Bcl-2 protein inhibitors are being tested in clinical trials. Preclinical 
studies seem promising, especially in combination with additional chemotherapy agents. 
Ongoing and planned phase II clinical trials to define the activity of single agents and drug 
combinations will determine the direction of future clinical development of the Bcl-2 
inhibitors [84]. 
4- PUMA (p53 upregulated modulator of apoptosis) is a BH3-only Bcl-2 family member and a 
critical mediator of p53-dependent and -independent apoptosis induced by a wide variety of 
stimuli, including genotoxic stress, deregulated oncogene expression, toxins, altered redox 
status, growth factor/cytokine withdrawal and infection. It serves as a proximal signalling 
molecule whose expression is regulated by transcription factors in response to these stimuli. 
PUMA transduces death signals primarily to the mitochondria and acts indirectly on the Bcl-
2 family members Bax and/or Bak by relieving the inhibition imposed by anti-apoptotic 
members. It directly binds and antagonizes all known anti-apoptotic Bcl-2 family members to 
induce mitochondrial dysfunction and caspase activation [87]. Several lines of evidence 
suggest that the function of PUMA is compromised in cancer cells. PUMA expression was 
found to be reduced in malignant cutaneous melanoma, and PUMA expression appears to be 
an independent predictor of poor prognosis in patients [88]. In addition, approximately 40% 
of primary human Burkitt’s lymphomas do not express detectable levels of PUMA, which is 
attributable, in part, to DNA methylation [89]. Evidence of PUMA induction by therapeutic 
agents in patients has just begun to emerge. Analysis of tissue biopsies from breast cancer 
patients showed that PUMA mRNA was induced within 6 h of chemotherapy [90]. Increased 
expression of PUMA and Bim is associated with better prognosis in patients receiving 5-FU-
based therapy in stage II and III colon cancer, and is an independent prognostic marker for 
overall and disease-free survival [91]. PUMA ablation or inhibition leads to apoptosis 
deficiency underlying increased risks for cancer development and therapeutic resistance. 
Although elevated PUMA expression elicits profound chemo- and radio-sensitization in 
cancer cells, inhibition of PUMA expression may be useful for curbing excessive cell death 
associated with tissue injury and degenerative diseases. Therefore, PUMA is a general sensor 
of cell death stimuli and a promising drug target for cancer. 
5- The apoptosome, a complex of cytochrome-c and APAF-1, recruits and activates the 
initiator pro-caspase 9, leading to the activation of the effector caspases, in particular pro-
caspase 3, culminating in those biochemical and morphological changes associated with 
apoptotic cell death [92]. This pathway is further regulated by the inhibitor of caspase protein 
XIAP, which works through the direct inhibition of active caspases 9 and 3 [93] and is also 
implicated in the ubiquitination of caspases, targeting them for proteasomal degradation [94]. 
Moreover there is a direct interaction between XIAP and its antagonist Smac [95].  
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Because of the importance of this pathway in cancer progression and chemotherapy-induced 
cell death, apoptosome-associated proteins may be important markers for colorectal cancer 
prognosis and chemotherapy response. Several studies have examined the 
immunohistochemical expression of individual proteins associated with apoptosis execution 
in colorectal cancer [96]. Increased expression of APAF-1 has been shown to be associated 
with longer patient survival in rectal cancer patients [97] and loss of APAF-1 has been 
implicated in tumour progression and more aggressive disease [98]. Similarly, longer overall 
survival has been associated with increased Smac [99] and caspase 9 [100]. The anti-apoptotic 
XIAP has also been implicated as a potential prognostic marker for colorectal cancer, with 
increased expression correlating with poor patient outcome [101]. However, no study to date 
has provided a comprehensive analysis of these key regulatory proteins as markers for 
colorectal cancer prognosis or chemotherapy response. Recently, the pro-caspase 3 expression 
in colorectal tumours has been associated with better recurrence-free and overall survival, 
and serves as an independent prognostic marker in localised Stage II disease [102]. This result 
is in agreement with previous studies that demonstrated as caspase 3 expression is a positive 
prognostic marker in hepatocellular carcinoma [103] and diffuse large B-cell lymphoma [104].  
6- The extrinsic apoptosis pathway is triggered by the binding of death ligands of the 
tumour necrosis factor (TNF) family to their appropriate death receptors (DRs) on the cell 
surface. One TNF family member, TRAIL or Apo2L, seems to preferentially cause apoptosis 
of transformed cells and can be systemically administered in the absence of severe toxicity. 
Therefore, there has been enthusiasm for the use of TRAIL or agonist antibodies to the 
TRAIL DR4 and DR5 in cancer therapy. Nonetheless, many cancer cells are very resistant to 
TRAIL apoptosis in vitro. Therefore, there is much interest in identifying compounds that 
can be combined with TRAIL to amplify its apoptotic effects [105]. The combination of 
TRIAL DR agonists with numerous conventional and investigational anticancer drugs has 
been reported. Synergy has been described for the combination of TRAIL with a variety of 
cytotoxic agents including irinotecan, camptothecin, 5-FU, carboplatin, paclitaxel, 
doxorubicin, and gemcitabine in diverse preclinical models [106,107]. Many human and 
mouse cancer cells lines can be sensitized by proteasome inhibitors such as bortezomib 
(VELCADE) to the apoptotic effects of TRAIL DR agonists. Interestingly, non-transformed 
cells seem to be much more resistant to the apoptotic effects of bortezomib and TRAIL than 
are cancer cells. This suggests that a therapeutic window may exist in vivo where this 
combination may have a therapeutic benefit in the absence of accompanying toxicity. 
However, the molecular mechanism(s) of action whereby proteasome inhibition in cancer 
cells results in sensitization to TRAIL apoptosis remains unclear [108].  
3. Selective antitumour-drug inducers of apoptosis 
Improved clinical response may be obtained by identifying therapies that are particularly 
effective in activating apoptosis and determining how those therapies may be modified to 
effect maximum apoptosis induction. The cell cycle apparatus and apoptosis have attracted 
the attention of researchers intent on developing new types of anticancer therapy [109,110]. 
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We will concentrate in this part of the review on the evolution of the chemical structures 
and on the biological properties, whilst the chemical syntheses will be referred to through 
the corresponding original references. 
3.1. Benzo-fused seven-membered derivatives linked to 5-fluorouracil (5-FU) 
We have reported the synthesis and anticancer activities of compounds 1-5 [16] and trans-6 
[17] (Figure 1). In all cases, the linkage between the 5-FU moiety and the seven-membered 
ring was carried out through its N-1 atom. The structural nature of 5 implies that this 
compound cannot be considered as a 5-FU prodrug and it was suspected that the remaining 
compounds (1-6) would not be 5-FU prodrugs. 
O
O
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R2
5-FU
O
5-FU
O
OH
5FU
O
OO
O
5-FU5FU
5-FU
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1       R1 = R2 = H    R3 = F
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4
5 6
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Figure 1. Several 5-FU derivatives showing interesting anti-tumour activities. 
The IC50 values of the 5-FU cyclic O,N-acetals are shown in Table 1 (entries 4-9). The most 
active compounds are 1, 2 and 6 (entries 4, 5 and 9). On comparing structures 4 and 1, it is 
worth emphasizing that the bioisosteric change of carbon for oxygen and the saturation of 
the double bond in compound 1 increases the anti-proliferative activity two fold in (IC50 = 
7.00 ± 0.61 μM, entry 4). The introduction of a methoxy group into the benzene ring of 1 
provokes different influences on the anti-proliferative activities. Thus, the C-7 substitution 
produces an increase of the anti-proliferative activity (2, IC50 = 4.50 ± 0.33 μM, entry 5), 
whilst if C-9 is the substituted position it gives rise to a decrease in the anti-proliferative 
activity of 3 (IC50 = 22.0 ± 0.93 μM, entry 6). 
Apoptosis has been studied in terms of cancer development and treatment with attempts 
made to identify its role in chemotherapeutic agent-induced cytotoxicity. Cytotoxic agents 
often induce only a fraction of the cells to become apoptotic. To fully exploit apoptosis as a 
mechanism of anti-neoplastic agent response, a larger proportion of cells needs to be 
recruited into apoptosis. Paclitaxel (Taxol®), cyclophosphamide and cytosine arabinoside 
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are the only commonly used cytotoxic agents shown to elicit apoptosis in breast cancer cells 
[111,112]. Quantitation of apoptotic cells was done by monitoring the binding of fluorescein 
isothiocyanate (FITC)-labelled annexin V (a phosphatidylserine-binding protein) to cells in 
response to our title compounds as described [113]. The apoptosis study shows that 3, 4 and 
5, at their IC50 concentrations, provoke early apoptosis in the cells treated for 24 and 48 h. It 
is worth pointing out that 3 (entry 6) induces greater apoptosis at 48 h (46.73%) than at 24 h 
(40.08%). The compounds that show the most important apoptotic indexes at 24 h are 4 
(57.33%, entry 7) and 5 (54.33%, entry 8), whereas at 48 h is 4 (51.37%, entry 7). These 
compounds are more potent as apoptosis inductors against the MCF-7 human breast cancer 
cells than paclitaxel (Taxol®), which induced programmed cell death of up to 43% of the cell 
population [114]. Accordingly, the early apoptotic inductions and the low IC50 values give 
rise to a significant anti-tumour activity. 
Since the synthesized compounds induce very important apoptosis, we have carried out 
studies of the expression of some of the genes that intervene in this phenomenon, among 
which p53 and the family bcl-2 are outstanding. The tumour suppressor gene p53 protects 
the integrity of the genome so that if the DNA of the cell is damaged by an agent, an over-
expression of it is produced inducing the stopping in G1 for the repair of the damage, or if 
this is not possible, enter apoptosis [115]. On the other hand, the members of the family of 
proteins Bcl-2 work as regulators of apoptosis, Bcl-2 and Bcl-XL protecting against 
apoptosis. Bax, Bak and Bad induce such a phenomenon [116]. The treatment of the MCF-7 
cells (wild-type p53) with these compounds provoked in general an increase in the protein 
expression of p53, mainly for 5-FU and 4, and a marked decrease of the levels of bcl-2 for all 
of them. These data show that p53 activity is restored with the compounds, allowing the 
entrance of the tumour cells in apoptosis, which permits their elimination by this 
mechanism. In the same way bcl-2 inhibition facilitates the entrance of cells into the 
programmed cell death. 
 
Entry Compound IC50 (μM)a Cell Cycle (48 h)b Apoptosisc 
G0/G1 G2/M S 24 h 48 h 
1 Control  68.39 12.04 19.57  1.24 1.24 
2 5-FU 2.75 58.07 2.10 39.38  56.75 52.81 
3 Ftorafur 3.00  0.11 45.62 0.00 54.38  52.20 58.06 
4 1 7.00  0.61 74.41 15.77 9.82  8.45 12.17 
5 2 4.50  0.33 73.41 13.15 13.44  1.50 3.50 
6 3 22.0  0.93 71.76 10.08 18.16  40.08 46.73 
7 4 14.0  1.02 86.14 1.60 12.26  57.33 51.37 
8 5 69.0  2.31 68.61 9.60 21.79  54.33 35.49 
9 6 5.50  0.58 82.48 5.13 12.40  14.37 19.05 
aSee [117]. bDetermined by flow cytometry: see [16]. cApoptosis was determined using an annexin V-based assay [113]. 
The data indicate the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in 
duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 1. Anti-proliferative activitiy, cell cycle dysregulation, and apoptosis induction in the MCF-7 
human breast cancer cell line after treatment for 24 and 48 h for the compounds. 
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3.2. 1-[2-(2-hydroxymethylphenoxy)-1-methoxyethyl]-5-fluorouracils 7a-f: 
antiproliferative activity, cell cycle dysregulation and apoptotic induction 
against breast cancer cells  
Acyclic 5-FU O,N-acetals 7a-f were previously reported by us (Figure 2) [17]. The aminalic 
bond is established through N-1 of the 5-FU moiety. 
O
OMe
OH
R1
5-FUR2
7a  R1 = R2 = H
7b  R1 = H; R2 = OMe
7c  R1 = Cl; R2 = H
7d  R1 = Br; R2 = H
7e  R1 = NO2; R2 = H
7f  R1 = NH2; R2 = H  
Figure 2. Several acyclic 5-FU O,N-acetals previously reported by us [17]. 
The IC50 values of compounds are shown in Table 2. The most active compound is 7e (5.42 ± 
0.26 μM), with an anti-proliferative activitiy in the same order as that of Ftorafur (3.00 ± 0.11 
μM). Cell cycle regulation has attracted a great deal of attention as a promising target for 
cancer research and treatment. The use of cell-cycle-specific treatments in cancer therapy has 
greatly benefited from the major advances that have been recently made in the identification 
of the molecular actors regulating the cell cycle and from the better understanding of the 
connections between cell cycle and apoptosis. As more and more ‘cell cycle drugs’ are being 
discovered, their use as anticancer drugs is being extensively investigated [118]. To study 
the mechanisms of the anti-tumour and anti-proliferative activities of the compounds, the 
effects on the cell cycle distribution were analyzed by flow cytometry. DMSO-treated cell 
cultures contained 68.39% G0/G1-phase cells, 12.04% G2/M-phase cells and 19.57% S-phase 
cells. In contrast, MCF-7 cells treated during 48 h with the IC50 concentrations of 7a–f 
showed important differences in cell cycle progression compared with DMSO-treated 
control cells. The treatment with Ftorafur showed a decrease of the G0/G1-phase cells and a 
corresponding accumulation of S-phase cells (45.62% G0/G1-phase cells and 54.38% S-phase 
cells). Moreover, there was an almost total disappearance in the G2/M population of the cells 
treated with this drug. In general the cell cycle regulatory activities for the newly 
synthesized compounds can be divided into the following three groups: (a) 7c and 7d 
accumulated the cancerous cells in the G2/M-phase, in the former compound at the expense 
of the S-phase cells, and (b) 7e induced a S-phase cell cycle arrest (50.24%) in a similar 
percentage to that caused by Ftorafur (54.28%, Table 2). Therefore, it can be affirmed that the 
nitro derivative (7e) may act as a 5-FU prodrug. Nevertheless, this hypothesis needs to be 
corroborated by further assays. In response to 40a, the percentage of apoptotic cells 
increased, from 1.24% in control cells to a maximum of 59.9% apoptotic cells (24 h) at a 
concentration equal to its IC50 against the MCF-7 cell line. This is a remarkable property 
because the demonstration of apoptosis in MCF-7 breast cancer cells by known apoptosis-
inducing agents has proved to be difficult and only few cytotoxic agents act preferentially 
through an apoptotic mechanism in human breast cancer cells [113,114]. Finally, a fact worth 
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emphasizing is that 7e (the only compound tested) induced neither toxicity nor death in 
mice after one-month treatment when administered intravenously twice a week, with a 50 
mg/kg dose each time. 
 
Compound IC50 (M)a Cell cycle (48 h)b Apoptosis (h)c 
 G0/G1 G2/M S 24 48 
Control 68.39 12.04 19.57 1.24 1.24 
O
5-FU
 
Ftorafur 
3.00 ± 0.11 45.62 0 54.38  52.20 58.06 
7a 18.5 ± 0.95 67.18 4.67 28.16 59.90 40.23 
7b 29.0 ± 1.63 62.72 1.59 35.69 33.35 37.87 
7c 18.0 ± 0.85 71.01 28.99 0.00 44.36 50.64 
7d 16.0 ± 1.18 51.45 20.66 27.88 42.24 36.37 
7e 5.42 ± 0.26 46.92 2.84 50.24 40.73 48.22 
7f 21.0 ± 1.02 67.32 9.40 23.28 41.15 37.81 
aSee [117]. bDetermined by flow cytometry: see [16]. cApoptosis was determined using an annexin V-based assay [113]. 
The data indicate the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in 
duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 2. Anti-proliferative activitiy, cell cycle dysregulation, and apoptosis induction in the MCF-7 
human breast cancer cell line after treatment for 24 and 48 h for the compounds. 
3.3. Benzo-Fused Seven-Membered Derivatives Linked To Purines 
Compounds 8-10 (Figure 3) were synthesized as reported. 
O
O
N
N
N
N
R
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N
R   8   R = OCH2CH=CH2
  9   R = SC6H5
10  R = SC6H3-Cl2-(2,4)
 
Figure 3. Several cyclic O,N-acetals reported by us [119]. 
The anti-tumour potential of the target molecules is stated against the MCF-7 human breast 
cancer cell line (Table 3). The most active compound (8), that presents an allyloxy group as 
substituent at position 6 of the purine ring, shows an IC50 = 5.04 ± 1.68 μM nearly equipotent 
as 5-FU. Compounds, 9 and 10, present bulky substituents as the phenylthio and 2,4-
diclorophenylthio ones, respectively. 
To study the mechanisms of the anti-tumour and anti-proliferative activities 8-10, the effects 
on the cell cycle distribution were analyzed by flow cytometry (Table 3). DMSO-treated cell 
cultures contained a 58.62 ± 0.74 of the G0/G1-phase cells, a 33.82 ± 0.72 of the S-phase cells 
and a 7.55 ± 1.34 of the G2/M-phase cells. In contrast, MCF-7 cells treated during 48 h with 
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the IC50 concentrations of 8, 9 and 10 showed important differences in cell cycle progression 
compared with DMSO-treated control cells. The cell cycle regulatory activities can be 
divided into the following two groups: (a) the breast cancer cells showed an accumulation in 
the S-phase, up to 37.00 ± 2.00 of the cells, mainly at the expense of the G0/G1-phase 
population that decreased to a percentage of 55.63 ± 1.57 of the cells; (b) compounds 9 and 
10 accumulated the cancerous cells in the G2/M-phase (11.08 ± 1.01 and 19.16 ± 0.56, 
respectively) at the expense of the S-phase cells (26.82 ± 1.26 and 22.73 ± 0.37, respectively). 
In response to 9 (and 10), the percentage of apoptotic cells increased, from 0.22 ± 0.31 in 
control cells to a maximum of 73.37 ± 0.12 (and 65.28 ± 1.92) apoptotic cells at a 
concentration equal to their IC50 against the MCF-7 cell line. This is a remarkable property 
because the demonstration of apoptosis in MCF-7 breast cancer cells by known apoptosis-
inducing agents has proved to be difficult. 
 
Compound Cell cyclea Apoptosisb 
 IC50 (μM) G0/G1 S G2/M  
Control  58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
8 5.04 ± 1.68 55.63 ± 1.57 37.00 ± 2.00 7.37 ± 0.43 44.47 ± 2.98 
9 7.12 ± 0.46 59.10 ± 1.28 26.82 ± 1.26 11.08 ± 0.01 73.37 ± 0.12 
10 8.40 ± 0.91 58.10 ± 0.19 22.73 ± 0.37 19.16 ± 0.56 65.28 ± 1.92 
a Determined by flow cytometry. 3 bApoptosis was determined using an Annexin V-based assay [120]. The data indicate 
the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in duplicate and gave 
similar results. The data are means ± SEM of three independent determinations. 
Table 3. Anti-proliferative activity, cell cycle distribution and apoptosis induction in the MCF-7 human 
breast cancer cell line after treatment for 48 h for the three most active compounds. 
3.4. Anti-cancer activity of 9-(2,3-Dihydro-1,4-benzoxathiin-3-ylMethyl)-9H-purines 
Compounds 1-6 may be considered as drugs with their own entity and anti-tumour activity 
independent of that of 5-FU. If the previously described compounds are not prodrugs, it is 
not necessary to maintain the O,N-acetalic characteristic with the corresponding weakness 
of the O,N-acetalic bond. Therefore, molecules are being designed in which both structural 
entities (such as the benzo-heterocyclic ring and the purine base) are linked by a 
heteroatom-C-C-base-N-atom bond. The design, synthesis and biological evaluation of a 
series of 2- and 6-disubstituted 9-(2,3-dihydro-1,4-benzoxathiin-3-ylmethyl)-9H-purine 
derivatives 11-13 were described (Figure 4, Table 4) [121]. 
O
S
N
N
N N
R2
R1
11  R1 = H, R2 = Cl
12  R1 = H; R2 = Br
13  R1 = Cl; R2 = Cl
 
Figure 4. Several non-acetalic purine derivatives reported by us [121]. 
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Compounds 11-13 were subjected to cell cycle and apoptosis studies on the MCF-7 human 
breast cancer cell line (Table 4). The following two consequences can be stated: (a) in 
contrast to 5-FU, the six-membered compounds 11-13 provoked a G0/G1-phase cell cycle 
arrest when the MCF-7 cells were treated during 48 h with the IC50 of the compounds, 
mainly at the expense of the S-phase populations. The fact that at similar doses the novel 
derivatives exhibit different sequences of cell cycle perturbations in comparison with 5-FU 
indicates that these compounds act by different pathways [12]. In the case of 12 it is worth 
pointing out that, moreover, there is an increase in the G2/M-phase of the cancerous cells; 
and (b) the apoptotic indices of the target compounds are very important, especially for 13 
(58.29% for 11, 63.05% for 12, and 76.22% for 13). Up to now and according to our 
knowledge, compound 13 is the most important apoptotic inducer against the MCF-7 
human breast cancer cell line so far reported. 
 
Compound  Cell cyclea Apoptosisb 
 IC50 (μM) G0/G1 S G2/M  
Control  58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
5-FUc 4.32 ± 0.02 58.07 ± 0.11 39.38 ± 0.98 2.10 ± 0.12 52.81 ± 1.05 
11 10.6 ± 0.66 69.71 ± 1.50 23.73 ± 1.65 6.56 ± 0.17 58.29 ± 0.75 
12 6.18 ± 1.70 62.85 ± 0.87 26.71 ± 1.25 10.43 ± 0.38 63.05 ± 0.26 
13 8.97 ± 0.83 70.30 ± 0.32 23.67 ± 2.40 6.06 ± 2.72 76.22 ± 2.02 
aDetermined by flow cytometry [12]. bApoptosis was determined using an Annexin V-based assay [12]. The data 
indicate the percentage of cells undergoing apoptosis in each sample. cData were taken from [117]. All experiments 
were conducted in duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 4. Anti-proliferative activity, cell cycle distribution and apoptosis induction in the MCF-7 human 
breast cancer cell line after treatment for 48 h for the three most active compounds as anti-proliferative 
agents. 
3.5. Anti-cancer activity of cyclic and acyclic O,N-acetals derived from purines 
and 5-FU 
We have recently published two O,N-acetals with outstanding anti-proliferative activities. The 
most potent antiproliferative agent against the MCF-7 adenocarcinoma cell line belongs to the 
benzoxazepine O,N-acetalic family is 9-[1-(9H-fluorenyl-9-methoxycarbonyl)-1,2,3,5-
tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine (14, IC50 = 0.67 ± 0.18 M), whilst 7-{2-
(N-hydroxymethylphenyl)-2-nitrobenzenesulfonamido]-1-methoxyethyl} -6-chloro-7H-purine 
(15) shows the lowest IC50 value among the family of acyclic O,N-acetals (IC50 = 3.25 ± 0.23 M) 
(Figure 5). The global apoptotic cells caused by 14 and 15 against MCF-7 were 80.08% and 
54.85% of cell population after 48 h, respectively. cDNA microarray technology reveals 
potential drug targets, which are mainly centred on positive apoptosis regulatory pathway 
genes, and the repression of genes involved in carcinogenesis, proliferation and tumour 
invasion [21]. We demonstrated later on that, when the anthranilic alcohol-derived acyclic 5-
fluorouracil O,N-acetal 16 was administered to human breast cancer cells MCF-7, had no 
activity against classic pro-apoptotic genes such as p53, and even induced the down-regulation 
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of anti-apoptotic genes such as Bcl-2. In contrast, several pro-apoptotic genes related with the 
endoplasmic reticulum (ER)-stress-induced apoptosis, such as BBC3 and Noxa, appeared up-
regulated. These results seem to show that the mechanism of action and selectivity of 16 was 
via the activation of the ER-stress-induced apoptosis. The linkage between the 5-FU moiety 
and the chain of 16 is through the N-1 atom of the pyrimidine [20] (Figure 5). 
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Figure 5. Several O,N-acetalic purine derivatives reported by us [20,21]. Fmoc is the 
fluorenylmethyloxycarbonyl group; oNs is the -SO2-C6H4-oNO2 group. 
4. Inhibitor of apoptosis protein (IAP) family as therapeutic target 
In the apoptotic pathway, the balance between pro and anti-apoptotic proteins is tightly 
regulated, so an imbalance directed to the anti-apoptotic regulation involves the apparition 
of survival advantages onto the initiating cancerous cells. In this way, the role of the IAPs 
family proteins is important. This family was first identified in baculovirus and the main 
characteristic is the presence of a baculovirus IAP repeat (BIR) domain, that mediates 
interactions with a number of proteins, including caspases and also other structural 
domains such as a RING or caspase activation recruitment domain (CARD) [122] (Figure 6). 
In the IAP family we can find proteins involved in the inhibition of apoptosis through 
inhibition of caspases or modulation of the nuclear factor kB (NF-kB) signalling pathways. 
This family includes eight members in mammals (BIRC1– BIRC8), also known as neuronal 
apoptosis inhibitory protein (NAIP), cellular IAP1 (cIAP1) and IAP2 (cIAP2), Xchromosome 
linked IAP (XIAP), survivin, Apollon (BRUCE), livin (ML-IAP) and ILP2 [123] (Figure 6).  
4.1. Role of the IAPs in apoptosis 
As long as apoptosis pathway must be tightly regulated, the IAPs are the only known 
regulatory proteins that control the activity of both initiator and effectors caspases in the 
process. In this way, there are studies where XIAP was found to prevent caspase-3 
processing in response to caspase-8 activation. So it is suggested that XIAP is able to inhibit 
this extrinsic apoptotic signaling by blocking the downstream effectors caspases, avoiding 
the direct interference of the caspase-8 activation [124]. 
On the other hand, other IAPs proteins are not potent inhibitors of caspases, such as c-IAP 
proteins. They are able to bind with Smac having high affinities to prevent it from blocking 
XIAP-mediated inhibition of caspases. These IAPs also show a E3 ubiquitin ligase activity, 
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allowing the regulation of several cell death effectors and modulators, playing a key role in 
cellular survival. c-IAP1 and c-IAP2 are able to interact with TNFα-receptor-associated 
factors -1 and -2 (TRAFs) trough their association in a complex with TNFα receptor 2. The 
TNFα receptor can mediate survival and death cell signals. In this case, c-IAP1 and c-IAP2 
have been proposed to reduce the level of caspase-8 activation and protect cells from 
apoptosis in a TNFα relationship [10]. 
 
Figure 6. Identifying some of the structural motifs of IAPs. The baculoviral IAP repeat (BIR) domains; 
70–80-amino-acid cysteine- and histidine-rich domains that chelate zinc ions. The presence of at least 
one BIR domain is the defining characteristic of the IAP family. The number of BIR domains in a given 
IAP varies from one to three. Another motif is the really interesting new gene (RING) zinc finger, a 
caspase recruitment domain and ubiquitin-associated (UBA) domains are found in individual IAPs. 
Finally, the CARD motif (Caspase Recruitment Domain) is a protein–protein interaction domain that 
mediates oligomerization with other CARD-containing proteins and is found in a number of proteins 
involved in the regulation of cell death. 
There is another family member of the IAPs, called Livin, which are expressed in high levels 
in melanoma and colon cancer, in embryonic tissues and transformed cells. The over-
expression of Livin isoforms α and β blocks apoptosis induced via the extrinsic death 
receptor pathway [125]. 
Survivin is involved in the control of cell proliferation and cell death and gene expression is 
regulated in a cell cycle dependent manner in mitosis. The spliced transcription of the 
survivin gene gives rise to wild-type survivin, survivin-2α, survivin-2B, survivin-ΔEx-3 and 
survivin-3B. This protein is stabilized by phosphorylation thanks to a p34cdc2–cyclin B1 
complex during mitosis. The anti-apoptotic function of survivin has been linked with its 
interaction with Smac/DIABLO, with the stabilization of XIAP protein through its binding to 
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XIAP and with the inhibition of mitochondrial and apoptosis-inducing factor-dependent 
apoptotic pathways [126]. 
Other IAPs is Bruce/Apollon which is a membrane bounded protein involved in protein 
ubiquination-mediated degradation by its ability to target proteins thanks to the presence of 
a C-terminus E2 motif. It is also shown that Bruce is able to bind to caspase -3, -7 and -9 
[127]. In Bruce regulation are involved the E2 UbcH5 and the E3 Nrdp1, which ubiquitinate 
the epidermal growth factor receptor family member, ErbB3. It has been shown that a 
decrease in Bruce content by Nrdp1 over-expression induces apoptosis in different cell lines. 
These studies suggest that this IAP protein play a critical role in apoptosis inhibition in 
certain cell types avoiding pro-caspase-9 cleavage when it binds to this protein [128]. 
Naip has been studied because of the clinical relevance in tumors such as prostate or breast 
cancer. Naip has two different functions; in the first one it is involved in the inflammatory 
process by caspase-1, -4 and -5 activation, and the second one is via apoptosis regulation by 
caspase-3 and -7 inhibition [129]. Davoody et al showed the cleavage inhibition of procaspase-
3 by apoptosome activated caspase-9 and the inhibition of the autocatalytic processing of 
procaspase-9 in the apoptosome complex. This fact indicates that unlike other IAPs, Naip is 
an inhibitor of procaspase-9 [130].  
Finally, Ts-IAP, also known as ILP-2, is the product of a human testis-specific mRNA and is 
related to the C-ter region of another member of the IAPs protein family, XIAP. It is showed 
that this protein is a weak caspase-9 inhibitor, and also a highly unstable molecule. 
However, a stabilized form of this protein containing nine additional N-ter residues may 
form a complex with Smac/DIABLO [131]. 
4.2. Use of IAPs into clinic: prognostic and therapeutic values  
The expression and/or function of IAPs are deregulated in many human cancers because of 
genetic aberrations, an increase in their mRNA or protein expression or the loss of 
endogenous inhibitors such as Smac. The expression levels of IAPs and their antagonists 
have been correlated with clinical parameters and cancer prognosis in several retrospective 
trials. However, these results should be interpreted with caution due to the low numbers of 
samples studied in some reports and the limitations of currently available reagents for 
analyzing the expression of IAP proteins in tissue specimens. Therefore, additional studies 
are required to evaluate the prognostic value of IAPs in human malignancies [10].  
The issue of primary or acquired resistance to current chemotherapeutic-based treatments is 
a major impediment to effective cancer treatment. Although there are many genetic and 
biochemical alterations that occur in cancer cells, in vitro experiments demonstrate that the 
up-regulation of IAPs expression increases resistance to chemotherapy and radiation. The 
fundamental role of the IAPs in apoptosis regulation and their elevated expression in many 
tumour types suggest that there is value in exploiting the inhibition of IAP expression and 
function as a direct therapeutic strategy [125].  
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Novel drugs have been developed and some of them are in current clinical trials. Several 
strategies have been chosen for anticancer drug development targeting IAP molecules: (1) 
small-molecule IAP antagonists, (2) antisense oligonucleotides (ASOs), (3) Smac mimetic 
molecules and others [132]. Small-molecule IAP antagonists and antisense oligonucleotides 
have garnered the most attention. Also, IAP antagonists have been extensively studied in 
combination with other cytotoxic agents including anticancer drugs, small-molecule signal 
transduction inhibitors, proteasome inhibitors and death receptor ligands as well as with 
radiation therapy. 
4.2.1. Small-molecule IAP antagonists 
Owing to the differences in the mechanism of caspase inhibition by the BIR 2 and BIR 3, 
domain molecules have been developed to specifically target the BIR 2 or BIR 3 region of 
XIAP. The structural data surrounding the interaction between the BIR 3 domain of XIAP 
and caspase-9, suggests that small molecules that bind the BIR 3 pocket of XIAP could 
mimic the action of Smac and inhibit the interaction between XIAP and caspase-9. These 
structural studies have facilitated a variety of chemical biology approaches including 
fluorescent polarization, nuclear magnetic resonance, ‘in silico’ virtual screening and 
computer modelling to identify BIR 3 inhibitors [133]. The first small-molecule XIAP 
inhibitors were reported by [134]. These inhibitors were identified using a high throughput 
enzymatic derepression assay in which recombinant XIAP was combined with active 
caspase-3 to inhibit caspase-mediated cleavage of the fluorogenic peptide substrate. With 
this assay, they screened 160.000 compounds in 1536-well format and identified potent XIAP 
inhibitors including the compounds TWX006 and TWX024, aryl sulphonamides with 
flexible acyclic diamines in the first and third fragments. These compounds derepressed 
XIAP-mediated inhibition of caspase-3 more potently than Smac. In addition, these 
molecules bound the BIR 2-linker region of XIAP, and, in enzymatic assays, relieved the 
repression of caspase-3 more potently than Smac peptides.  
Recently, small-molecule phenylurea-based chemical inhibitors of XIAP were identified by 
large-scale combinatorial library screening. Subsequent studies have confirmed that the 
active XIAP inhibitors, but not their inactive structural analogues, could induce apoptosis in 
a variety of human cancer cell lines and xenograft. Furthermore, it was determined that 
these XIAP inhibitors act by binding to its BIR-2 domain, resulting in elevated activity of the 
downstream caspase-3 and caspase-7. Thus, the action of these exogenous XIAP inhibitors 
was found to be mechanistically distinct from that of the endogenous inhibitor second 
modulator of apoptotic proteases, which predominantly binds to the BIR-3 domain [135]. 
4.2.2. Antisense oligonucleotides 
The single-stranded antisense oligodeoxynucleotides (AS ODNs) are short stretches of 
synthetic DNA, approximately 12–30 nucleotides long, and are complementary to a specific 
mRNA strand. Hybridization of the AS ODNs to the mRNA by Watson–Crick base pairing 
prevents the target gene from being translated into protein, thereby blocking the action of 
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the gene, and resulting in the degradation of the target mRNA. The specificity in the AS 
ODN approach is based on the fact that any sequence of approximately 13 bases in RNA 
and 17 bases in DNA is estimated to be represented only once in the human genome. AS 
ODNs targeting survivin expression in human lung adenocarcinoma cell lines decreased 
survivin protein levels in a dose-dependent manner, induced apoptosis, stimulated higher 
levels of caspase-3 activation, and increased the sensitivity of cells to chemotherapeutics. 
XIAP AS ODNs effectively down-regulated both specific mRNA and protein levels in 
human non-small cell lung cancer growth both in vitro and in vivo. XIAP AS ODNs 
effectively induced apoptosis on their own and sensitized the tumor cells to the cytotoxic 
effects of several chemotherapeutics, including Taxol, etoposide and doxorubicin [26]. 
Furthermore, the administration of XIAP AS ODNs in a xenograft model of human non-
small cell lung cancer results in a significant down-regulation of XIAP protein [124]. 
AEG35156 is a 19-mer oligonucleotide targeting XIAP. Its sequence was designed to achieve 
maximal stability and potency and to minimize immunostimulation through avoiding CpG 
motifs. Phase I studies in patients with refractory malignancies established safety [136]. A 
phase I/II study of AEG35156 in combination with idarubicin and high-dose cytarabine in 
patients with relapsed or refractory AML demonstrated a dose-dependent knock-down of 
XIAP mRNA and protein and a promising response rate [137]. The molecule may rapidly 
enter randomized studies in AML while being also tested in lymphomas. The dose-limiting 
toxicity of an antisense oligonucleotide designed to inhibit surviving mRNA expression 
(LY2181308) was headache and the compound demonstrated some biological efficacy in 
decreasing survivin expression [138]. A phase II study has opened in solid tumours. The 
locked nucleic acid strategy was used to design other survivin-targeting antisense 
oligonucleotides, including SPC3042 [139] and EZN-3042 [140], which are currently being 
evaluated in Phase I clinical trials as single agents and in combination with cytotoxic drugs. 
4.2.3. Smac-mimicking IAP antagonist 
Smac mimetics may be a useful therapeutic target as over-expression of Smac may 
potentiate apoptosis by neutralizing the caspase-inhibitory function of IAPs. Following the 
discovery that an IAP-binding motif consisting of four NH2-terminal amino acid residues 
was sufficient to bind to the BIR3 domain of XIAP, Smac-peptide mimetics were constructed 
which were capable of competing with caspase-9, displacing it from the BIR3 domain of 
XIAP. The three members of the IAP family, XIAP, cIAP1, and cIAP2, are structurally 
homologous (XIAP amino acid sequence identity to cIAP1 and cIAP2 of 36% and 39%, 
respectively, the amino acid sequence identity between cIAP1 and cIAP2 is 70%). In 
particular, the BIR3 IBM region is well conserved among the three IAPs. The XIAP BIR3 
residues involved in van der Waals contacts (Val298, Lys299, and Trp310) and hydrogen 
bonds (Gly306, Leu307, and Trp323) with the inhibitory compounds are conserved. Minor 
exceptions are Leu292, replaced by Val in the cIAPs, Glu314 substituted by Asp in both 
cIAPs, and Gln319, which is Glu325 in cIAP1, and Gln311 in cIAP2. Finally, residues Thr308 
and Asp309 that were found relevant for Smac-mimetics interaction with XIAP BIR3, are 
replaced by Arg314/Arg300 and Cys315/ Cys307 in cIAP1/cIAP2, respectively [127].  
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Smac interacts with IAPs via its N-terminal tetrapeptide, Ala1- Val2-Pro3-Ile4 (AVPI). Using 
this structural information, several groups designed small molecules mimicking AVPI to 
derive proteolytically stable compounds. Monovalent Smac mimetics were designed to 
mimic the Smac AVPI-binding motif and so target the XIAP-BIR3 domain. They exhibit high 
affinities, not only to XIAP-BIR3 but also to cIAP1, cIAP2 and MLIAP proteins. Bivalent 
Smac mimetics, containing two AVPI-binding motifs, bind to XIAP-BIR2–BIR3 with an 
extremely high affinity, exceeding that of Smac protein. Preclinical profiling studies have 
shown that Smac mimetics effectively sensitize cancer cells to other therapeutic agents, but 
they are also capable as single agents of inducing apoptosis in some but not all human 
cancer cell lines. To date, two Smac mimetics have reached phase I clinical development, 
and approximately ten are in an advanced preclinical development stage and are expected 
to enter human clinical testing soon [141].  
Smac mimetic binds to XIAP and induces cIAP degradation. There are two cellular events 
that result from cIAP degradation: (1) activation of the non-canonical NF-κB pathway and 
subsequently increased production of autocrine TNF-α and (2) release of RIP1 from the 
TNF-α receptor complex, leading to caspase-8 activation, which requires TNF-α receptor to 
be activated in the first place. Accumulating evidence suggests that whether or not Smac 
mimetic induces autocrine TNF-α production is the key factor in deciding the cell's fate 
upon Smac mimetic treatment. Depending on their response to Smac mimetics cells can be 
grouped into three general classes: in class I cells, Smac mimetic induces autocrine TNF-α 
production and massive cell loss; in class II cells, Smac mimetic still induces autocrine TNF-
α production but this does not have a major effect on the cell population; and in class III 
cells, Smac mimetic has no effect on autocrine TNF-α production or on cell death. The ability 
of cells to produce TNF-α is necessary but not sufficient for Smac mimetic to induce cell 
death as a single agent [142].  
5. miRNA-based therapy 
The miRNAs, is a class of endogenous, small, non-coding RNAs of 18–25 nucleotides in 
length, that negatively regulates gene expression by degradation of mRNA or suppression 
of mRNA translation. Mature miRNA products are formed in from a longer primary 
miRNA (pri-miRNA) transcript through sequential processing by the ribonucleases Drosha 
and Dicer1 [143,144]. miRNAs are known to repress thousands of target genes because only 
partial complementarity to the target mRNA is required. Thus, one miRNA may be 
simultaneously targeting a complexity of mRNAs as well as the expression of a single 
mRNA may be regulated by many miRNAs [143].  
The miRNAs are involved in normal processes, including cellular development, differentiation, 
proliferation, apoptosis, and stem cell self-renewal [28].The aberrant expression or alteration of 
miRNAs contributes to a range of human pathologies, including cancer. Furthermore, the 
deregulation of miRNA causes evasion of apoptosis which involved tumourigenesis and drug 
resistance [122]. During tumour initiation and progression, the functionality of aberrant 
miRNAs may act as oncogenes (OncomiRs) or tumour suppressors (TSmiRs), a numbers of 
 
Apoptosis and Medicine 130 
them are strongly related to the apoptosis phenomenon. Therefore, manipulation of miRNA 
expression levels which target genes and pathways that are involved in apoptosis could be a 
potential therapeutic strategy for developing efficient therapies against cancer. In addition, 
given that cancer cells often exhibit a distinctive pattern of miRNA expression, unique profiles 
of altered miRNAs expression could be useful as molecular biomarkers for tumour diagnosis, 
prognosis of disease-specific outcomes, and evaluation of tumour aggressiveness. Based on this, 
several anticancer therapies focusing on restoring miRNA activities and repairing gene 
regulatory networks or drug sensitivity are being developed. 
There are two strategies of molecular therapy targeted at miRNA, one by the inhibition of 
oncogenic miRNAs and the other the over-expression of tumour suppressor miRNAs.  
5.1. Targeting oncogenic miRNAs 
The oncomiRs could be blocked by different approaches such as (i) antisense 
oligonucleotides, (ii) antagomirs, (iii) locked nucleic acid (LNA) constructs or (iv) sponges 
[145]. Antisense oligonucleotides work as competitive inhibitors of miRNA, leading to the 
up-regulation of tumour suppressor proteins, inducing apoptosis and blocking tumour 
formation in vitro and in vivo. Some of the potential ways to enhance miRNA stability 
include chemical modifications. In order to improve their effectiveness and stability, 
antisense oligonucleotides, have been modified on their 50 end, by adding 20-O-methyl and 
20-O-methoxyethyl groups [146]. Oligonucleotides with 2′-O-methyl groups have proved to 
be effective inhibitors of miRNA expression in several cancer cell lines [30,147,148,149]. The 
utility of anti-miRNA oligonucleotide in vivo through intravenous injection of modified 
anti-miRNA oligonucleotide O-methyl-modified cholesterol-conjugated single stranded 
RNA analogues has been studied, with phosphorothioate linkages, an ‘antagomirs’, to target 
the liver-specific miR-122. Specific miR-122 silencing for up to 23 days was conferred with 
only a single injection of 240 mgkg-1 body weight [150]. 
On the other hand, the locked-nucleic-acid antisense oligonucleotides exhibit relatively low 
toxicity and have been optimized by reducing their molecular size which has increased their 
therapeutic potential [151]. LNA anti-miR’ constructs have been used successfully in several 
in vitro studies to knock down specific miRNA expression [151,152]. Also it has showed that 
miR-221 and miR-222 knockdown through antisense LNA oligonucleotides increases 
p27Kip1 in human prostate cancer (PC3) cells and strongly reduces their clonogenicity in 
vitro [153]. In vivo, the use of LNAs has achieved unexpected success for the treatment of 
hepatitis C in non-human primates [154]. These finding demonstrate the impressive 
potential of this strategy to overcome a major hurdle for clinical miRNA therapy.  
Moreover, other techniques have emerged as an effective way to repress expression levels of 
miRNA families. A new form of miRNA inhibitors that can be transiently expressed in cultured 
mammalian cells, “miRNA sponges”, was developed. Sponges are ectopically expressed 
mRNAs that contain multiple miRNA target sites of miRNA that share the same seed sequence 
[155]. In contrast to miRNA sponges, Xiao et al. designed alternative strategy called “miRNA 
masking” which covers up the miRNA-binding site to depress its target mRNA [156]. 
 
Apoptosis as a Therapeutic Target in Cancer and Cancer Stem Cells: Novel Strategies and Futures Perspectives 131 
Although several in vitro and in vivo technologies have been developed to inhibit the 
oncomiRs, it is still a long and arduous way to go for substantial applications of miRNAs in 
cancer treatments. To date, many OncomiRs seem to have a role in apoptosis (Table 5), 
therefore some have been regarded as hallmarks in tumour progressions and hot targets in 
cancer therapy. Thus, miR-21 is functionally considered oncogenic because it is 
overexpressed in various tumours [157,158]. In fact, antisense inhibition of miR-21 leads to 
the induction of programmed cell death in neuroepithelial cells, through activation of 
caspases [159]. This apoptosis induction was also confirmed in breast cancer, colon cancer, 
pancreas cancer, lung cancer, liver cancer, prostate cancer, stomach cancer and oral squamous 
cell carcinoma (OSCC) [31,160,161,162,163]. So far, multiple targets of miR-21 have been 
identified and mapped to anti-apoptotic signalling pathways which suggest a promising 
miRNA treatment for cancer [31,164]. Other examples have been reported; in breast cancer 
cells, the overexpresion of the anti-apoptotic Bcl-2 is restored by the silencing of miR-15a and 
miR-16 through the use of specific inhibitors [165]. As the anti-apoptotic Bcl-2 is frequently 
overexpressed in a number of human cancers, such as Hodgkin’s lymphoma, cell lymphoma 
and breast, miR-15 and miR-16, it could be used for therapy of cancer-associated phenotypes.  
 
miRNA Function Gene target Cancer Type Reference(s) 
miR-221, 
miR-222 
OncomiRs PTEN 
p27kip1 
Bim 
PUMA 
Hepatocarcinoma,  
melanoma, glioblastoma, 
lung, prostate cancer, 
leukemia, gastric carcinoma 
[153,166,167,168,
169,170] 
miR-21 OncomiRs PTEN 
PDCD4 
Bcl-2 
Fas L 
Non-small cell lung cancer, 
breast, prostate, gastric, 
hepatocellular cancer, 
colorectal cancer, 
glioblastoma and leukemia 
[31,157,164,165,1
71,172,173,174,17
5]  
miR-17-92 
cluster 
OncomiRs PTEN, BIM, 
p21 
 
Lymphoma, lung, breast, 
stomach, colon and 
pancreatic cancer  
[176,177] 
miR-29a, 
miR-29b 
 and miR-
29c 
Tumour 
suppressor 
CDC42 and 
p85a (up-
regulating 
p53), Bcl-2 
Lymphocytic leukaemia, 
cholangiocarcinomahepatoc
arcinoma, colon, breast, and 
lung cancer 
[148,149,178,179] 
miR-34 
family 
Tumour 
suppressor 
Bcl-2, SIRT1 Prostate cancer 
non-small-cell lung cancer 
and neuroblastoma  
[180,181,182,183] 
miR-15a, 
miR-16-1,  
Tumour 
suppressor 
Bcl-2, Mcl1, 
PDCD6IP 
Leukemia, gastric cancer 
cells and prostate cancer  
[30,184,185] 
Let 7 Tumour 
suppressor 
Bcl-Xl Lung, colon, stomach, 
ovarian and breast cancer. 
[186,187,188,189,
190] 
Table 5. Key microRNAs involved in apoptosis 
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5.2. Restoration of tumour suppressor miRNAs 
The restoration of tumour suppressor miRNAs, as a therapeutic strategy, includes viral 
delivery or synthetic miRNA mimics. Elevation of the expression levels of miRNAs can 
restore tumour inhibitory functions in cancer cells. Adeno-associated virus delivery of 
miRNAs or miRNA antagonists has the advantage of being efficient and because the virus 
does not integrate into the genome, non-mutagenic. In Myc-induced liver tumours, 
intravenous injection of adeno-associated virus 8 (AAV8)-expressing miR-26 resulted in the 
suppression of tumourigenicity by inducing tumour-apoptosis, without signs of toxicity 
[191]. These findings indicate a possibility strategy for the treatment of liver cancer, 
however, before this approach achieve widespread clinical use, the delivery and safety of 
different treatments needs to be improved.  
Another strategy to increase the expression of a tumour-suppressor miRNA in cancer could 
be overcome by miRNA mimics, which are small, chemically modified double-stranded 
RNA molecules designed to mimic endogenous mature miRNAs [192]. Introduction of 
synthetic miRNA mimics with tumour-suppressor function in cancer cells have been 
implicated to induce cell death and block proliferation in several studies 
[30,147,178,184,186]. In prostate and AMl cell lines mimics of miR-15a and miR-29 
respectively, induced apoptosis by repression of anti-apoptotic genes Mcl-1 and Bcl-2 [184]. 
Multiple miRNAs have been found to inhibit the apoptotic pathway following their over 
expression during cancer development. Reduced expression of miR-15, miR-16, and let-7 has 
been observed in different types of cancers and as one consequence anti-apoptotic genes and 
apoptotic signalling pathways have been activated in these cancer cells [30,187,193]. As well, 
transfection of anti-miR-24 oligonucleotides has been proved to induce apoptosis in several 
cell lines [194]. It has been reported that miR-195, miR-24-2 and miR-365-2 act as negative 
regulators of the anti-apoptotic proto-oncogene Bcl2. The overexpression of these miRNAs 
caused an increase in apoptosis and also augmented the apoptotic effect of etoposide in 
breast cancer MCF7 cells [195]  
5.3. miRNAs and drug resistance 
Several miRNA, some of them related to apoptosis, have been associated with drug 
resistance. Deregulation of miR-214 is a recurrent event in human ovarian cancer and it has 
been shown that miR-214 induces cell survival and cisplatin resistance primarily through 
targeting the PTEN/Akt pathway [196]. Also, is known that the let-7 family of miRs plays a 
role in a host of cellular functions such as modulation of drug sensitivity. The miRNA let-7a 
which directly targeting caspase-3 is over-expressed in some human cancers and has been 
shown to induce resistance to a variety of drugs caspase-3-dependent apoptosis, including 
doxorubicin, paclitaxel and interferon-gamma. Let-7e was up-regulated in some ovarian 
cancer cell lines with increased resistance to doxorubicin. On other hand, it has been 
reported that let-7i is down-regulated in chemotherapy-resistant ovarian cancer, and 
reintroduction of let-7i can sensitize resistant ovarian cancer cell lines to platinum-based 
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chemotherapy [188]. In a non small cell lung cancer cell line, the down-regulation of miR-
186* which increased the expression of its direct target, Caspase-10, has been indicated the 
cause of the apoptosis induced by the chemopreventive agent curcumin [189]. Thus, the 
effect of anti-cancer drugs that modulate cell proliferation apoptosis on miRNA expression 
profiles was explored and could help for predicting apoptosis resistance. As a result, the 
knowledge of potential miRNAs implicated in apoptosis resistance could avoid unnecessary 
morbidity and may represent a novel class of biomarkers for facilitating personalized 
treatment. 
6. Cancer stem cells and apoptosis 
Some cancers are originated in cells with intrinsic self-renewal activity or in differentiated 
cells in which self-renewal is activated by oncogenic mechanisms; hence, the study of 
normal self-renewal is important to improve our understanding of these mechanisms. 
Cancers express a spectrum of aberrantly differentiated cells, ranging from those that 
appear well differentiated to those that appear undifferentiated, and these phenotypes are 
commonly evident in the same tumour. This suggests that the transformation process can 
induce defects throughout the multistep differentiation process. Recent data suggest that 
cancers arise from rare self-renewing stem cells that are biologically distinct from their more 
numerous differentiated progeny. A small number of cells identified as cancer stem cells 
(CSCs) from solid tumours usually express organ-specific markers, contribute to 
chemotherapy resistance and are able to generate a new tumour in immunodeficient mice. 
Moreover, there is growing evidence that pathways regulating normal stem cell self-renewal 
and differentiation are also present in cancer cells and CSCs [197]. 
Currently, there are two theories on the origin of cancer: the classic clonal evolution theory 
or stochastic model, by which malignant transformation results from random mutations and 
subsequent clonal selection of cancer cells with similar potential to regenerate the tumour 
growth [198,199]; and the CSC hypothesis, which considers the tumour to be formed by a 
small population of cells with stem cell-like properties. The features in common with stem 
cells are: indefinite self-replication, asymmetric cell division, and resistance to toxic agents, 
owing, in part, to elevated expression of ABC transporters [199,200,201]. In addition, they 
are also characterized by genetic instability (chromosomal and microsatellite), changes of 
chromatin, transcription and epigenetics, mobilization of cellular resources, and modified 
microenvironment interactions (tumour cells, stromal cells, extracellular, endothelium) 
[202]. Both paradigms of tumour propagation are likely to exist in human cancer but only 
the CSC model is hierarchical. It is important to note that the two models are not mutually 
exclusive, as CSCs undergo clonal evolution, as shown for leukaemia stem cells [203]. 
The theory of cancer stem cells is not new, having started wonderings in the 19th century 
when comparing cancerous and embryonic tissue in the microscope and certain similarities 
were observed, annotating the idea that tumours arising from embryonic-like cells. This 
theory continued to evolve, and the isolation of four different tumour subpopulations from 
a single breast cancer in a mouse was reported in the decade of the 80s[204]. Tumour 
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heterogeneity is reflected in different phenotypic aspects such as cell morphology, gene 
expression, metabolism, motility and proliferation, immunogenic, angiogenic and metastatic 
potential [202]. 
 
Figure 7. A. The clonal evolution model of cancer is based on the fact that accumulation of a series of 
mutations (inhibition of apoptosis, angiogenesis,…) in any somatic cell can cause a tumour. B. The 
cancer stem cell model is based on the principle that a progenitor cell capable of self-renewal and 
proliferation (stem cell characteristics) is the cause of formation of a tumour. 
TUMOUR TYPE MARKERS Reference 
Hematological malignancies CD34+ / CD38- [207] 
CNS CD133+ [208] 
Colon CD133+/ EpCAMhi / CD44+ / 
CD166+ 
[209,210] 
Breast CD24-/low /CD44+ [211] 
Lung CD133+ [212] 
Pancreas CD44+ / CD24+ / EpCAM+/ CD133+ [213] 
Liver  CD90+ [214] 
Prostate CD44+ / CD133 / α2β1hi [215] 
Bladder CD44+ / CK5+/ CD20- [216] 
Ovaries CD44+ / CD117+ [217] 
Head and neck CD44+ [218] 
Melanoma ABCB5+ [219] 
Table 6. Phenotypic markers of CSCs in various tumours. 
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Molecular characterization of CSCs is necessary to develop a targeted therapy (Table 6). 
They have been isolated from several tumour types including haematological malignancies 
(the first evidence) [205], breast, brain, colon, lung, head and neck, prostate, pancreas and 
liver cancers and melanoma. The subpopulation of CSCs self renews, differentiates, and 
regenerates a phenocopy of the original tumour when injected into immunodeficient mice 
[206]. 
Tumour stem cells may display multidrug resistance that is conferred by ABC transporters. 
These ABC transporters have been reported as CSCs markers in melanoma and 
osteosarcoma, among others. These transporters are up-regulated in CSCs, and the low-
staining fraction of cells with the ability to efflux Hoechst 33342 dye is commonly known as 
the side population (SP) [33]. Targeted inactivation of ABC transporters could reinstate drug 
sensitivity in CSCs, resulting in their death. Moreover, pathways that regulate self-renewal 
of normal stem cells, such as Wnt, Notch and Hedgehog, tumor suppressor genes, such as 
PTEN and p53, have been implicated in the control of CSCs self-renewal. These pathways 
are believed to be deregulated in CSCs, leading to uncontrolled self-renewal and generation 
of tumours that are resistant to conventional therapies [220]. The above mentioned 
characteristics and the ability of CSCs to evade cell death signals contribute to the failure of 
existing therapies to eradicate malignant tumours, causing resistance to treatment and an 
increased morbidity and mortality [201,221]. Apoptosis is one of the most critical and well-
studied mechanisms, governing tissue development and homeostasis through a complex 
network of molecules that mediate death and survival signals. Escape from death program 
is a prerequisite for any tumour-initiating cell and may support the survival of CSCs in 
response to chemo- or radio-therapy. Thus, manipulating the apoptotic machinery to 
eradicate tumour-initiating cells holds enormous therapeutic potential [206]. 
Several studies have focused on apoptosis induction in CSCs by intervening in the extrinsic 
or intrinsic pathways to treat cancer. 
6.1. TRAIL 
TRAIL has been demonstrated to induce apoptosis in a wide range of cancer types both in 
vitro and also in various mouse models of human cancers [106]. In certain types of tumours 
a correlation has been established between the expression of DR and CSCs. Chemotherapy-
resistant colon cancer SP cells express high levels of DR4 [222]; in some bladder cancer cell 
lines there is an increased expression of DR5 [223], and, in glioblastoma and lung CSCs 
express DRs [206]. More importantly, several clinical trials have explored the response to the 
use of DRs as a treatment. Studies concluded that SP cells of colon cancer displayed higher 
sensitivity to TRAIL compared to the non-SP cells [222]. In bladder cancer treatment 
sensitivity was greater in those showing increased expression of DR5 [223]. Moreover, 
isolated neurospheres from glioblastomas with characteristics of stem cells showed 
differences in apoptosis after treatment with TRAIL and it was effective in those who keep 
the route intact for caspase 8. Genomic heterogeneity in glioblastomas suggests the presence 
of multiple mechanisms in TRAIL resistance in both CSCs and non-stem cells. Future 
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clinical trials of TRAIL apoptotic pathway targeted therapies may consider genomic analysis 
of tumour tissue to identify the genomic status of TRAIL apoptotic genes such as caspase 8 
and use it as a genomic marker to predict tumour resistance to TRAIL apoptotic pathway-
targeted therapies [224]. In addition, recent studies are focused on combining mesenchymal 
stem cells (MSCs) expressing TRAIL and chemotherapy. These MSCs migrated to tumours 
and reduced the growth of primary cancers and metastases by induction of apoptosis, death 
and reduced colony formation of the SP and were synergistic when combined with 
traditional chemotherapy in apoptosis induction [225]. 
6.2. cFLIP 
cFLIP is overexpressed in many types of cancers like melanoma, colon lymphoma and 
thyroid cancer [226]. The CD133+ populations within the T-cell acute leukemia cell line 
Jurkat and the breast cancer cell line MCF7 were reported to express higher levels of cFLIP, 
which was associated with TRAIL resistance. The down-regulation of cFLIP using siRNA 
restored TRAIL signalling in both cell lines resulting in a dramatic reduction in 
experimental metastases and the loss of CSC self-renewal [227]. This suggests that a 
combined TRAIL/FLIPi therapy could prevent metastatic disease progression in cancers. 
6.3. IAP 
In CD133 + cells isolated from glioblastoma an increased mRNA expression of livin, 
survivin and the multidrug resistance-associated protein 1 (MRP1) was detected. Therefore, 
the effects of etoposide, a pro-apoptosis agent, on these associated protein genes in 
glioblastoma stem-like cells have been studied. Results showed that after etoposide 
treatment, glioblastoma CSCs displayed a stronger resistance to apoptosis and death. The 
anti-apoptotic gene livinβ was more related with the high survival rate and MRP1 was more 
related with transporting chemotherapeutic agent out of glioblastoma stem-like cells [228]. 
In pancreatic cancer it has been demonstrated that targeting XIAP by RNAi inside the cancer 
cells, the combination of TRAIL with MSCs suppressed metastatic growth in these tumours 
[229]. Recently, it has been demonstrated that survivin is regulated by the interleukin-4 (IL-
4) pathway in colon CSCs. Blockage of IL-4-mediated signaling pathway with leflunomide, 
Stat6 inhibitor, increased the nuclear survivin pool suggesting that the IL-4/STAT-6 pathway 
could escape cell death. IL-4 neutralization, mediated by STAT-6, could down-regulate 
survivin expression and localization, increasing the nuclear pool and in this way inducing 
chemo-sensitivity of CSCs [230].  
6.4. Bcl-2  
The proteins Bcl-2 family members are anti-apoptotic molecules known to be over-
expressed in most cancers, and are associated directly with the CSCs [231]. Therefore, recent 
studies are aimed to target these proteins. A representative example is found in pancreatic 
cancer, against which the most potent and clinically acceptable Bcl-2 inhibitor AT-101 is 
currently in 20 different clinical trials around the world [232]. In glioblastoma, high 
 
Apoptosis as a Therapeutic Target in Cancer and Cancer Stem Cells: Novel Strategies and Futures Perspectives 137 
expression levels of the anti-apoptoticc Bcl-2 protein, Mcl-1, were associated with resistance 
to treatment with Bcl-2 inhibitor ABT-737 in glioma stem cells [233]. In hematopoietic 
malignances, it has been showed that despite the over-expression of Bcl-2 this is not the 
critical point for the generation, selection and maintenance of leukemia stem cells [234].  
6.5. NF-kB 
The transcription factor NF-κB has been connected to multiple aspects of oncogenesis, 
including inhibition of apoptosis by increasing the expression of survival factor. In fact, 
aberrant regulation of NF-κB has been observed in many cancers, including both solid and 
hematopoietic tumours [235]. A fairly representative example is found in pancreatic cancer, 
where there is a clear correlation between the basal activity of NF-kB and the ability to 
generate angiogenesis and metastasis of pancreatic tumour cells [236] and, more recently it 
has been found that not only in this way, but also in the non-canonical NF-kB is also 
activated and functional [237]. A very interesting study by [238] showed that in CD44+ 
breast CSCs the expression of CD24 potentiated DNA-induced apoptosis by suppressing 
anti-apoptotic NF-κB signaling. Several therapies are being developed to inhibit this factor 
because there are many tumours which relate the decrease in the activity of NF-kB with a 
decrease in the size and tumor growth [239,240,241,242,243]. 
6.6. DNA repair capacity 
A classic mechanism involved in the induction of apoptosis is in response to DNA damage 
by p53 action. This gene is mutated in most human cancers and inactivated in about 50% of 
cancers [244]. p53 was found to repress the CSC marker gene CD44 in an experimental 
breast tumour model and the over-expression of CD44 blocked p53-dependent apoptosis, 
leading to expansion of tumour-initiating cells [245]. Moreover, glioma CSCs resist radiation 
through preferential activation of the retainer DNA damage response and an increase in 
DNA repair capacity. In addition, the radioresistance of CD133+ glioma stem cells could be 
reversed with a specific inhibitor of Chk1 and Chk2 checkpoint kinases [208]. Another 
report reinforces the tumour-promoting effect of DNA damage response activation in 
leukemia stem cells by demonstrating that cell-cycle inhibitor p21 was indispensable for 
maintaining self-renewal of these CSCs [246]. 
6.7. miRNAs, apoptosis and CSCs 
Recently, miRNAs have emerged as key regulators of "stemness", collaborating in the 
maintenance of pluripotency, control of self-renewal, and differentiation of stem cells. 
Moreover, certain miRNAs involved in apoptosis appear to influence the CSC fate by 
controlling self-renewal. It has been shown that restoration of miR-34 modulates self-
renewal in pancreatic CSCs by directly regulating down-stream target gene Notch and Bcl-2 
[247]. Also the restoration of miR-34, inhibit p53-mutant gastric cancer tumourspheres 
growth in vitro and tumour formation in vivo, which is reported to be correlated to the self-
renewal of CSCs [248]. As miR-34 is a significant tumour suppressor of CSCs by regulation 
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of both apoptosis and self-renewal properties, restoration of miR-34 may hold significant 
promise for a novel molecular therapy. Data also suggest that let-7 regulates apoptosis and 
CSC differentiation, which is considered as a key “keeper” of the differentiated state. In this 
context decreased expression of these TSmiRs implicated in self-renewal could lead to 
further cancer progression. 
7. Conclusion 
In this chapter we have summarized the research in the discovery of molecules, biomarkers 
for predicting therapeutic response and regulatory pathways implicated in apoptosis 
induction. These strategies are contributing to design cancer-targeted therapies that 
diminish or circumvent toxicity and improve life quality and overall survival of patients. 
The selective eradication of cancer cells can be achieve with small molecules and 
monoclonal antibodies, used as single agents or in combination with conventional 
chemotherapy, that interfere with the deregulated cellular signals that promote proliferation 
and survival to block tumor growth or sensitize cancer cells to apoptosis while leaving 
normal cells unaffected. Moreover, targeted therapies reactivating death program in CSCs 
may synergize with established therapies and increase efficacy in the clinic.  
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